Rikio Suzuki

1.3k total citations
30 papers, 666 citations indexed

About

Rikio Suzuki is a scholar working on Hematology, Molecular Biology and Pathology and Forensic Medicine. According to data from OpenAlex, Rikio Suzuki has authored 30 papers receiving a total of 666 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Hematology, 18 papers in Molecular Biology and 6 papers in Pathology and Forensic Medicine. Recurrent topics in Rikio Suzuki's work include Multiple Myeloma Research and Treatments (15 papers), Protein Degradation and Inhibitors (7 papers) and Cancer Mechanisms and Therapy (4 papers). Rikio Suzuki is often cited by papers focused on Multiple Myeloma Research and Treatments (15 papers), Protein Degradation and Inhibitors (7 papers) and Cancer Mechanisms and Therapy (4 papers). Rikio Suzuki collaborates with scholars based in Japan, United States and Singapore. Rikio Suzuki's co-authors include Teru Hideshima, Paul G. Richardson, Francesca Cottini, Kenneth C. Anderson, Hiroto Ohguchi, Güllü Görgün, Naoya Mimura, Diana Cirstea, Jana Jakubı́ková and Nikhil C. Munshi and has published in prestigious journals such as Nature Communications, Blood and PLoS ONE.

In The Last Decade

Rikio Suzuki

25 papers receiving 661 citations

Peers

Rikio Suzuki
Andrea Kühnl United Kingdom
Alice Cani Italy
Ignazia Tusa Italy
Rosemary A Fryer United Kingdom
Dan Cojocari Canada
Keyi Zhu United States
Cathy E. Nolan United States
Shane W. O’Brien United States
Ryan A. Denu United States
Ján Gurský Czechia
Andrea Kühnl United Kingdom
Rikio Suzuki
Citations per year, relative to Rikio Suzuki Rikio Suzuki (= 1×) peers Andrea Kühnl

Countries citing papers authored by Rikio Suzuki

Since Specialization
Citations

This map shows the geographic impact of Rikio Suzuki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rikio Suzuki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rikio Suzuki more than expected).

Fields of papers citing papers by Rikio Suzuki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rikio Suzuki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rikio Suzuki. The network helps show where Rikio Suzuki may publish in the future.

Co-authorship network of co-authors of Rikio Suzuki

This figure shows the co-authorship network connecting the top 25 collaborators of Rikio Suzuki. A scholar is included among the top collaborators of Rikio Suzuki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rikio Suzuki. Rikio Suzuki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Iwata, S., Masashi Miyaoka, Shinichiro Machida, et al.. (2025). ALK-negative anaplastic large cell lymphoma with <i>TP53</i> mutation developing during the administration of baricitinib for atopic dermatitis – A case report –. Journal of Clinical and Experimental Hematopathology. 65(1). 55–61.
3.
Seki, Toshiro, Rikio Suzuki, Yoshiyuki Manabe, et al.. (2024). Liposome-encapsulated progesterone efficiently suppresses B-lineage cell proliferation. Biochemistry and Biophysics Reports. 38. 101710–101710. 2 indexed citations
4.
Machida, Shinichiro, et al.. (2024). Acute myeloid leukemia with a ZMYND11::MBTD1 fusion gene following chemotherapy and radiotherapy for breast cancer: A case report. Leukemia Research Reports. 22. 100478–100478.
5.
Ishida, Tadao, Kiyoshi Ando, Rikio Suzuki, et al.. (2023). Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. International Journal of Hematology. 117(5). 729–737. 15 indexed citations
6.
Onizuka, Makoto, Eri Kikkawa, Shinichiro Machida, et al.. (2023). Association of CDKN2A/2B deletion with relapse after hematopoietic stem cell transplantation for acute lymphoblastic leukemia. PubMed. 6(3). 80–86. 2 indexed citations
7.
Harada, Kaito, Makoto Onizuka, Ryujiro Hara, et al.. (2022). Risk factors for lower respiratory tract disease and outcomes in allogeneic hematopoietic stem cell transplantation recipients with influenza virus infection. Journal of Infection and Chemotherapy. 28(9). 1279–1285.
8.
Murayama, Norie, Yusuke Kamiya, Rikio Suzuki, et al.. (2022). Low cerebrospinal fluid-to-plasma ratios of orally administered lenalidomide mediated by its low cell membrane permeability in patients with hematologic malignancies. Annals of Hematology. 101(9). 2013–2019. 2 indexed citations
9.
Suzuki, Rikio, et al.. (2021). Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma. International Journal of Hematology. 115(2). 233–243. 3 indexed citations
10.
Hara, Ryujiro, Makoto Onizuka, Kaito Harada, et al.. (2020). The Role of Hypertension and Renin-angiotensin-aldosterone System Inhibitors in Bleomycin-induced Lung Injury. Clinical Lymphoma Myeloma & Leukemia. 21(4). e321–e327. 5 indexed citations
11.
Ohguchi, Hiroto, Teru Hideshima, Manoj Bhasin, et al.. (2016). The KDM3A–KLF2–IRF4 axis maintains myeloma cell survival. Nature Communications. 7(1). 10258–10258. 75 indexed citations
12.
Cottini, Francesca, Teru Hideshima, Rikio Suzuki, et al.. (2015). Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discovery. 5(9). 972–987. 87 indexed citations
13.
Suzuki, Rikio, Shohei Kikuchi, Takeshi Harada, et al.. (2015). Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS ONE. 10(12). e0143847–e0143847. 19 indexed citations
14.
Cirstea, Diana, Loredana Santo, Teru Hideshima, et al.. (2014). Delineating the mTOR Kinase Pathway Using a Dual TORC1/2 Inhibitor, AZD8055, in Multiple Myeloma. Molecular Cancer Therapeutics. 13(11). 2489–2500. 24 indexed citations
15.
Mimura, Naoya, Teru Hideshima, Toshiyasu Shimomura, et al.. (2014). Selective and Potent Akt Inhibition Triggers Anti-Myeloma Activities and Enhances Fatal Endoplasmic Reticulum Stress Induced by Proteasome Inhibition. Cancer Research. 74(16). 4458–4469. 66 indexed citations
16.
Cirstea, Diana, Teru Hideshima, Loredana Santo, et al.. (2013). Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 27(12). 2366–2375. 47 indexed citations
17.
Suzuki, Rikio, Ralph Mazitschek, Güllü Görgün, et al.. (2013). Histone deacetylase 3 as a novel therapeutic target in multiple myeloma. Leukemia. 28(3). 680–689. 131 indexed citations
18.
Suzuki, Rikio, Makoto Onizuka, Minoru Kojima, et al.. (2007). Prognostic significance ofFLT3 internal tandem duplication andNPM1 mutations in acute myeloid leukemia in an unselected patient population. International Journal of Hematology. 86(5). 422–428. 8 indexed citations
19.
Shimada, Masako, Makoto Onizuka, Shinichiro Machida, et al.. (2007). Association of autoimmune disease‐related gene polymorphisms with chronic graft‐versus‐host disease. British Journal of Haematology. 139(3). 458–463. 19 indexed citations
20.
Hibasami, Hiroshige, T Tsukada, Rikio Suzuki, et al.. (1991). 15-Deoxyspergualin, an antiproliferative agent for human and mouse leukemia cells shows inhibitory effects on the synthetic pathway of polyamines.. PubMed. 11(1). 325–30. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrea Kühnl Breakdown of academic impact, for papers by Alice Cani Breakdown of academic impact, for papers by Ignazia Tusa Breakdown of academic impact, for papers by Rosemary A Fryer Breakdown of academic impact, for papers by Dan Cojocari Breakdown of academic impact, for papers by Keyi Zhu Breakdown of academic impact, for papers by Cathy E. Nolan Breakdown of academic impact, for papers by Shane W. O’Brien Breakdown of academic impact, for papers by Ryan A. Denu Breakdown of academic impact, for papers by Ján Gurský
Rankless by CCL
2026